A Vaxfectin®-Adjuvanted HSV-2 Plasmid DNA Vaccine Is Effective for Prophylactic and Therapeutic Use in the Guinea Pig Model of Genital Herpes

Vaccine- Netherlands

doi 10.1016/j.vaccine.2012.09.057

Full Text

Abstract

Available in

Date

November 1, 2012

Authors

Publisher

Elsevier BV

Related search

Duration of Protection From Live Attenuated vs. Sub Unit HSV-2 Vaccines in the Guinea Pig Model of Genital Herpes: Reassessing Efficacy Using Endpoints From Clinical Trials

PLoS ONE

Multidisciplinary

2019

English

A VP26-mNeonGreen Capsid Fusion HSV-2 Mutant Reactivates From Viral Latency in the Guinea Pig Genital Model With Normal Kinetics

English

A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection Against HSV-1 and HSV-2 Genital Infections

English

Effects of Anal Compared to Vaginal Inoculation Site on Primary/Recurrent Genital HSV-2 Disease in Guinea Pig Model. † 1023

English

The Burden of Infection With HSV-1 and HSV-2 in England and Wales: Implications for the Changing Epidemiology of Genital Herpes

Sexually Transmitted Infections

Dermatology

Infectious Diseases

2000

English

Proportion of Herpes Simplex Virus (HSV) Type 1 and Type 2 Among Genital and Extragenital HSV Isolates

Acta Dermato-Venereologica

Dermatology

Medicine

2002

English

HSV-2: In Pursuit of a Vaccine

Journal of Clinical Investigation

Medicine

2011

English

Painful Failure of Promising Genital Herpes Vaccine

Science

Multidisciplinary

Philosophy of Science

History

2010

English

Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs With the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated With Protection Against Recurrent Genital Herpes

English

Amanote Research

A Vaxfectin®-Adjuvanted HSV-2 Plasmid DNA Vaccine Is Effective for Prophylactic and Therapeutic Use in the Guinea Pig Model of Genital Herpes

Vaccine- Netherlands

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Duration of Protection From Live Attenuated vs. Sub Unit HSV-2 Vaccines in the Guinea Pig Model of Genital Herpes: Reassessing Efficacy Using Endpoints From Clinical Trials

A VP26-mNeonGreen Capsid Fusion HSV-2 Mutant Reactivates From Viral Latency in the Guinea Pig Genital Model With Normal Kinetics

A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection Against HSV-1 and HSV-2 Genital Infections

Effects of Anal Compared to Vaginal Inoculation Site on Primary/Recurrent Genital HSV-2 Disease in Guinea Pig Model. † 1023

The Burden of Infection With HSV-1 and HSV-2 in England and Wales: Implications for the Changing Epidemiology of Genital Herpes

Proportion of Herpes Simplex Virus (HSV) Type 1 and Type 2 Among Genital and Extragenital HSV Isolates

HSV-2: In Pursuit of a Vaccine

Painful Failure of Promising Genital Herpes Vaccine

Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs With the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated With Protection Against Recurrent Genital Herpes